HC Wainwright started coverage on shares of Aeglea Bio Therapeutics (NASDAQ:AGLE). HC Wainwright issued a buy rating and a $20.00 price target on the stock. The analysts wrote, “We base our $20 price target on probability-adjusted revenue forecasts for pegzilarginase in ARG1-D and our year end fully diluted net cash estimate of $2.55/share to arrive at our price target. We use the net present value of our revenue forecast through 2028, apply a 50% POS of pegzilarginase in 4x price/sales multiple for ARG1-D to arrive at a value of $4.40/share. We use a 20% discount rate for the NPV of the pipeline as it is within the typical range of 15-25% for products in development. Our P/S multiple of 4x is in line with Aeglea’s peers at approximately 2-5x.””
Clovis Oncology (NASDAQ:CLVS) had its buy rating reiterated by analysts at HC Wainwright. HC Wainwright currently has a $36.00 target price on the stock.
Foot Locker (NYSE:FL) had its buy rating reissued by analysts at Pivotal Research. The firm currently has a $66.00 target price on the stock, down from their previous target price of $73.00.
HyreCar (NASDAQ:HYRE) had its buy rating reaffirmed by analysts at Northland Securities. The firm currently has a $8.00 price target on the stock. The analysts wrote, “We come away from the call with a better understanding of the dealer side of HYRE’s business, market trends and the value-add for a dealer to be on the HyreCar platform. Brian Allan has 39 years of dealer experience and a lot of insight into dealers businesses and his slides were very helpful in understanding the trends affecting dealers. Key Points HYRE is basically bringing technology enablement to dealers so they can participate in this ride sharing marketplace and sell and service more cars and customers. Remember a dealer can sign up for HyreCar for free and start generating revenue right away. As Brian noted the dealer already has the inventory, parts and service, and people.””
Linde (ETR:LIN) had its buy rating reaffirmed by analysts at UBS Group AG.
Lumentum (NASDAQ:LITE) had its overweight rating reiterated by analysts at Piper Jaffray Companies. The firm currently has a $68.00 price target on the stock, down from their previous price target of $75.00.
Oragenics (NYSEAMERICAN:OGEN) had its buy rating reissued by analysts at HC Wainwright. The firm currently has a $2.00 price target on the stock. The analysts wrote, “We believe the Phase 2 study could report top-line results in early 2020. If AG013 could significantly reduce the duration and lower the incidence of 2 data may serve as one of the two pivotal data sets required to support regulatory filing, in our view. AG013 has been granted Fast Track designation in the U.S. and Orphan Drug status in Europe. In the wake of this update, we reiterate our Buy rating and $2 price target. Preclinical data of lantibiotics published. Lantibiotics have been developed to possess both strong antimicrobial properties as well as the ability to evade common resistance mechanisms. Last week, preclinical data of the company’s lantibiotic compound, OG253, were published in Toxicology and Applied Pharmacology.””
Qorvo (NASDAQ:QRVO) had its buy rating reiterated by analysts at Canaccord Genuity. The firm currently has a $76.00 target price on the stock, down from their previous target price of $87.00.
Consumer Edge began coverage on shares of Uber Technologies (NYSE:UBER). The firm issued an equal weight rating on the stock.
Verint Systems (NASDAQ:VRNT) had its outperform rating reiterated by analysts at Wedbush. The firm currently has a $70.00 target price on the stock, up from their previous target price of $63.00.
Canaccord Genuity began coverage on shares of X4 Pharmaceuticals (NASDAQ:XFOR). Canaccord Genuity issued a buy rating on the stock.
Receive News & Ratings for Aeglea Bio Therapeutics Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aeglea Bio Therapeutics Inc and related companies with MarketBeat.com's FREE daily email newsletter.